AZD 2066

Drug Profile

AZD 2066

Alternative Names: AZD2066

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Analgesics; Antidepressants; Antiulcers
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Depressive disorders; Gastro-oesophageal reflux; Neuropathic pain

Most Recent Events

  • 31 Dec 2011 Discontinued - Phase-I for Neuropathic pain in Japan (PO)
  • 31 Dec 2011 Discontinued - Phase-I for Neuropathic pain in Sweden (PO)
  • 31 Dec 2011 Discontinued - Phase-I for Neuropathic pain in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top